Ignite Creation Date:
2024-05-05 @ 10:36 PM
Last Modification Date:
2024-10-26 @ 10:21 AM
Study NCT ID:
NCT01144572
Status:
COMPLETED
Last Update Posted:
2014-02-14
First Post:
2010-06-14
Brief Title:
Quality of Life in Chinese Postmenopausal HR Early Breast Cancer EBC Patients During Adjuvant Aromatase InhibitorsAIs Treatment
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Prospective Multicenter Non-interventional Study to Evaluate Quality of Life in Chinese Postmenopausal HR EBC Patients During Adjuvant Aromatase InhibitorsAIs Treatment
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BC Qol NIS
Brief Summary:
The purpose of the study is to evaluate quality of life Qol in postmenopausal HR EBC patients during adjuvant AIs treatment in terms of the change of the trial outcome index TOI of the FACT-B questionnaire from baseline to 24 months This study will recruit approximately 500 patients from 21 sites in China The patients should be postmenopausal HR EBC patients who have already start adjuvant AIs treatment but within 7 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None